{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Iijima K"],"funding":["The Ministry of Health, Labour, and Welfare, Japan","Japan Agency for Medical Research and Development"],"pagination":["401-419"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8819987"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["33(2)"],"pubmed_abstract":["Background
Rituximab is the standard therapy for childhood-onset complicated frequently relapsing or steroid-dependent nephrotic syndrome (FRNS/SDNS). However, most patients redevelop FRNS/SDNS after peripheral B cell recovery.Methods
We conducted a multicenter, randomized, double-blind, placebo-controlled trial to examine whether mycophenolate mofetil (MMF) administration after rituximab can prevent treatment failure (FRNS, SDNS, steroid resistance, or use of immunosuppressive agents or rituximab). In total, 39 patients (per group) were treated with rituximab, followed by either MMF or placebo until day 505 (treatment period). The primary outcome was time to treatment failure (TTF) throughout the treatment and follow-up periods (until day 505 for the last enrolled patient)"],"journal":["Journal of the American Society of Nephrology : JASN"],"pubmed_title":["Mycophenolate Mofetil after Rituximab for Childhood-Onset Complicated Frequently-Relapsing or Steroid-Dependent Nephrotic Syndrome."],"pmcid":["PMC8819987"],"funding_grant_id":["JP15lk0201021","H25-iryogijutsu-ippan-008","JP18k0201082"],"pubmed_authors":["Araki Y","Shimizu M","Omori T","Kumagai N","Kubota T","Ohtsuka Y","Ninchoji T","Hamada R","Machida H","Ito S","Sako M","Tanaka S","Tanaka R","Ishikura K","Kaito H","Morohashi T","Japanese Study Group of Kidney Disease in Children","Ohwada Y","Fujita N","Horinochi T","Sakai T","Gotoh Y","Yamada T","Tanaka E","Nakamura H","Nozu K","Kamei K","Nakanishi K","Shima Y","Konishi A","Ikezumi Y","Oba M","Okamoto T","Iijima K","Yamamura T"],"additional_accession":[]},"is_claimable":false,"name":"Mycophenolate Mofetil after Rituximab for Childhood-Onset Complicated Frequently-Relapsing or Steroid-Dependent Nephrotic Syndrome.","description":"Background
Rituximab is the standard therapy for childhood-onset complicated frequently relapsing or steroid-dependent nephrotic syndrome (FRNS/SDNS). However, most patients redevelop FRNS/SDNS after peripheral B cell recovery.Methods
We conducted a multicenter, randomized, double-blind, placebo-controlled trial to examine whether mycophenolate mofetil (MMF) administration after rituximab can prevent treatment failure (FRNS, SDNS, steroid resistance, or use of immunosuppressive agents or rituximab). In total, 39 patients (per group) were treated with rituximab, followed by either MMF or placebo until day 505 (treatment period). The primary outcome was time to treatment failure (TTF) throughout the treatment and follow-up periods (until day 505 for the last enrolled patient)","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Feb","modification":"2026-07-09T12:17:38.649Z","creation":"2025-04-19T17:57:57.802Z"},"accession":"S-EPMC8819987","cross_references":{"pubmed":["34880074"],"doi":["10.1681/asn.2021050643","10.1681/ASN.2021050643"]}}